您好,欢迎访问福建省农业科学院 机构知识库!

VP2 virus-like particles elicit protective immunity against duckling short beak and dwarfism syndrome in ducks

文献类型: 外文期刊

作者: Xiao, Shifeng 1 ; Wang, Shao 1 ; Jiang, Dandan 1 ; Cheng, Xiaoxia 1 ; Zhu, Xiaoli 1 ; Lin, Fengqiang 1 ; Yu, Bo 1 ; Dong, 1 ;

作者机构: 1.Fujian Acad Agr Sci, Inst Anim Husb & Vet Med, 247 Wusi Rd, Fuzhou 350003, Peoples R China

2.Fujian Anim Dis Control Technol Dev Ctr, Fuzhou, Peoples R China

3.Putian Inst Agr Sci, Putian, Peoples R China

4.Univ Lancaster, Div Biomed & Life Sci, Lancaster, England

5.Cairo Univ, Dept Virol, Fac Vet Med, Giza, Egypt

关键词: Cherry Valley ducks; duckling short beak and dwarfism syndrome; protective immunity; virus‐ like particle

期刊名称:TRANSBOUNDARY AND EMERGING DISEASES ( 影响因子:5.005; 五年影响因子:4.622 )

ISSN: 1865-1674

年卷期:

页码:

收录情况: SCI

摘要: Duckling short beak and dwarfism syndrome virus (SBDSV), an emerging goose parvovirus, has caused short beak and dwarfism syndrome (SBDS) in Chinese duck flocks since 2015. Presently, there is no commercial vaccine against SBDS. In the present study, a virus-like particle (VLP)-based candidate vaccine was developed against this disease. A baculovirus expression system was used to express the SBDSV VP2 protein in Sf9 cells. Immunofluorescence assay, sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting were used to confirm protein expression. Furthermore, transmission electron microscopy was used to observe the formation of VLPs. VLPs were formulated into an oil-adjuvanted maternal vaccine to evaluate humoral responses in breeding ducks via latex particle agglutination inhibition assay (LPAI) and microneutralization assay. The offspring were challenged with SBDSV to test the protective efficacy. A single dose of SBDSV was able to induce the high level of LPAI antibodies in ducks, with LPAI and neutralization peak titres of 4.9 +/- 1.20 log2 and 7.1 +/- 1.20 log2, respectively, at 4 weeks post-vaccination (wpv). The average LPAI titre of yolk antibodies in duck eggs receiving 2 doses (first and boost doses) of the vaccine was 5.3 +/- 1.09 log2 at 4 weeks post-boost. The protective efficacy of the maternal vaccine was 87.5%-100%. These results indicate that SBDSV VLPs can be a promising vaccine candidate for controlling SBDS.

  • 相关文献
作者其他论文 更多>>